Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis

Liver International

Volumn 34, Issue 6, 2014, Pages 850-858

  Moratalla, Alba ^a,b   Gómez Hurtado, Isabel ^a,b   Santacruz, Arlette ^c   Moya, Ángela ^c   Peiró, Gloria ^d   Zapater, Pedro ^a,d   González Navajas, José M ^a,b   Giménez, Paula ^a   Such, José ^a,b,e   Sanz, Yolanda ^c   Francés, Rubén ^a,b,e  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CSIC   (Spain)

^c INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

B. pseudocatenulatum CECT7765; Bacterial translocation; Cirrhosis; Inflammation; Microbiota

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BACTERIAL ANTIGEN; BACTERIAL DNA; CARBON TETRACHLORIDE; CECT 7765; ENDOTOXIN; HYDROXYPROLINE; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; OCCLUDIN; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; BIFIDOBACTERIUM PSEUDOCATENULATUM; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; EXPERIMENTAL LIVER CIRRHOSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION; LAPAROTOMY; LIPID DIET; LIVER; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED; GENETICS; IMMUNOLOGY; INTESTINE; LIVER CIRRHOSIS, EXPERIMENTAL; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CARBON TETRACHLORIDE; DNA, BACTERIAL; ENDOTOXINS; ESCHERICHIA COLI; FEMALE; INTESTINES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MICE, INBRED BALB C; PROBIOTICS;

EID: 84902551158     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12380     Document Type: Article

References (37)

1. Berg RD. Bacterial translocation from the gastrointestinal tract. J Med 1992; 23: 217-44.
2. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
3. Campillo B, Pernet P, Bories PN, et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-9.
4. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482-6.
5. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56: 1283-92.
6. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-8.
7. Chang CS, Yang SS, Kao CH, Yeh HZ, Chen GH. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol 2001; 36: 92-6.
8. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.
9. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105.
10. Gomez-Hurtado I, Santacruz A, Peiro G, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS ONE 2011;6:e23037.
11. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-72.
12. Caplan MS, Miller-Catchpole R, Kaup S, et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Gastroenterology 1999; 117: 577-83.
13. Ruseler-van Embden JG, van Lieshout LM, Gosselink MJ, Marteau P. Inability of Lactobacillus casei strain GG, L. acidophilus, and Bifidobacterium bifidum to degrade intestinal mucus glycoproteins. Scand J Gastroenterol 1995;30:675-80.
14. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995; 78: 491-7.
15. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483-9.
16. Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-51.
17. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9.
18. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur J Gastroenterol Hepatol 2012; 24: 831-9.
19. Pereg D, Kotliroff A, Gadoth N, et al. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011; 27: 177-81.
20. Cano PG, Santacruz A, Trejo FM, Sanz Y. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet fed mice. Obesity.(Silver.Spring) 2013. In press.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
22. Gomez-Hurtado I, Zapater P, Bellot P, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology 2011; 53: 935-44.
23. Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-41.
24. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl(4)-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44: 633-9.
25. Santacruz A, Collado MC, Garcia-Valdes L, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 2010; 104: 83-92.
26. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-82.
27. Soriano G, Sanchez E, Guarner C, Schiffrin EJ. Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. J Hepatol 2012; 57: 1395-6.
28. Frances R, Zapater P, Gonzalez-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47: 978-85.
29. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
30. Chen L, Pan DD, Zhou J, Jiang YZ. Protective effect of selenium-enriched Lactobacillus on CCl4-induced liver injury in mice and its possible mechanisms. World J Gastroenterol 2005; 11: 5795-800.
31. Young SL, Simon MA, Baird MA, et al. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clin Diagn Lab Immunol 2004; 11: 686-90.
32. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-7.
33. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456.
34. Bauer TM, Fernandez J, Navasa M, Vila J, Rodes J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002; 36: 501-6.
35. Segain JP, de la Raingeard BD, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403.
36. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res 2003; 1: 855-62.
37. Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. Nutrients 2011; 3: 118-34.